Form 4: ResMed Director Exercises Options, Sells Shares for Tax

ResMed Director Peter C. Farrell exercised 11,442 stock options and subsequently sold 7,314 shares to cover tax obligations.

Summary

• Peter C. Farrell, a Director of ResMed Inc. (RMD), reported changes in his beneficial ownership of company stock.
• On November 14, 2025, Mr. Farrell acquired 11,442 shares of ResMed Common Stock at an exercise price of $101.64 per share through the automatic exercise of fully vested options.
• Following this acquisition, his direct beneficial ownership of non-derivative securities was 77,552 shares.
• Concurrently, on November 14, 2025, Mr. Farrell disposed of 7,314 shares of ResMed Common Stock at a price of $244.46 per share.
• This disposition was made to the issuer for tax withholding purposes and to cover the cost of exercising the options granted on November 14, 2018.
• After these transactions, Mr. Farrell's direct beneficial ownership of non-derivative securities stands at 70,238 shares.
• The derivative securities (options) for 11,442 shares, with an exercise price of $101.64, were fully exercised and are no longer beneficially owned.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving option exercise and subsequent share sale for tax purposes, which is neutral in sentiment. It does not indicate any significant positive or negative developments for the company.

Positives

• The exercise of options by a director can be seen as a sign of confidence in the company's long-term prospects.
• The exercise price of $101.64 was significantly lower than the sale price of $244.46, indicating a substantial gain for the director on the exercised options.

Negatives

• The sale of 7,314 shares, even for tax purposes, reduces the director's direct ownership stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Peter C. Farrell holds the title of Chairman emeritus.

Industry Context

This Form 4 filing details a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The transaction represents a minor, routine change in a director's ownership, unlikely to have a significant impact on shareholder sentiment or company valuation.

Key Dates

Keywords

ResMed, RMD, Peter C. Farrell, Director, Stock Options, Insider Transaction, Share Sale, Tax Withholding, Beneficial Ownership